NCT04656613View on ClinicalTrials.gov

A Phase III Clinical Trial of the Immunogenicity and Safety of the Gam-COVID-Vac Vaccine Against COVID-19 in the UAE

PHASE3UnknownINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

December 31, 2020

Primary Completion Date

August 31, 2021

Study Completion Date

December 31, 2021

Conditions
Covid19SARS-CoV Infection
Interventions
BIOLOGICAL

Gam-COVID-Vac

the Gam-COVID-Vac is combined 2 -component vector vaccine against the SARS-СoV-2-induced coronavirus infection

OTHER

placebo

Placebo Comparator

Sponsors

Collaborators (1)

PDC-CRO
All Listed Sponsors
collaborator

PDC-CRO

UNKNOWN

lead

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

OTHER